Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urticaria facticia Treatment with Omalizumab
DRKS00004643Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omalizumab in Dermatographia (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Started Jan 2013; status: completed.
02
Drugs
omalizumab
03
Conditions
Dermatographia
Beyond the preview
Go deeper on DRKS00004643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004643.